These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
421 related articles for article (PubMed ID: 27440270)
1. Branched Chain RNA In Situ Hybridization for Androgen Receptor Splice Variant AR-V7 as a Prognostic Biomarker for Metastatic Castration-Sensitive Prostate Cancer. Saylor PJ; Lee RJ; Arora KS; Deshpande V; Hu R; Olivier K; Meneely E; Rivera MN; Ting DT; Wu CL; Miyamoto DT Clin Cancer Res; 2017 Jan; 23(2):363-369. PubMed ID: 27440270 [TBL] [Abstract][Full Text] [Related]
2. AR-V7 Transcripts in Whole Blood RNA of Patients with Metastatic Castration Resistant Prostate Cancer Correlate with Response to Abiraterone Acetate. Todenhöfer T; Azad A; Stewart C; Gao J; Eigl BJ; Gleave ME; Joshua AM; Black PC; Chi KN J Urol; 2017 Jan; 197(1):135-142. PubMed ID: 27436429 [TBL] [Abstract][Full Text] [Related]
3. Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer. Antonarakis ES; Lu C; Luber B; Wang H; Chen Y; Nakazawa M; Nadal R; Paller CJ; Denmeade SR; Carducci MA; Eisenberger MA; Luo J JAMA Oncol; 2015 Aug; 1(5):582-91. PubMed ID: 26181238 [TBL] [Abstract][Full Text] [Related]
4. The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients. Del Re M; Biasco E; Crucitta S; Derosa L; Rofi E; Orlandini C; Miccoli M; Galli L; Falcone A; Jenster GW; van Schaik RH; Danesi R Eur Urol; 2017 Apr; 71(4):680-687. PubMed ID: 27733296 [TBL] [Abstract][Full Text] [Related]
5. Novel Junction-specific and Quantifiable In Situ Detection of AR-V7 and its Clinical Correlates in Metastatic Castration-resistant Prostate Cancer. Zhu Y; Sharp A; Anderson CM; Silberstein JL; Taylor M; Lu C; Zhao P; De Marzo AM; Antonarakis ES; Wang M; Wu X; Luo Y; Su N; Nava Rodrigues D; Figueiredo I; Welti J; Park E; Ma XJ; Coleman I; Morrissey C; Plymate SR; Nelson PS; de Bono JS; Luo J Eur Urol; 2018 May; 73(5):727-735. PubMed ID: 28866255 [TBL] [Abstract][Full Text] [Related]
6. Androgen Receptor Modulation Optimized for Response-Splice Variant: A Phase 3, Randomized Trial of Galeterone Versus Enzalutamide in Androgen Receptor Splice Variant-7-expressing Metastatic Castration-resistant Prostate Cancer. Taplin ME; Antonarakis ES; Ferrante KJ; Horgan K; Blumenstein B; Saad F; Luo J; de Bono JS Eur Urol; 2019 Dec; 76(6):843-851. PubMed ID: 31542304 [TBL] [Abstract][Full Text] [Related]
7. Standardization of CTC AR-V7 PCR assay and evaluation of its role in castration resistant prostate cancer progression. Tommasi S; Pilato B; Carella C; Lasorella A; Danza K; Vallini I; De Summa S; Naglieri E Prostate; 2019 Jan; 79(1):54-61. PubMed ID: 30141201 [TBL] [Abstract][Full Text] [Related]
8. Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide. Antonarakis ES; Lu C; Luber B; Wang H; Chen Y; Zhu Y; Silberstein JL; Taylor MN; Maughan BL; Denmeade SR; Pienta KJ; Paller CJ; Carducci MA; Eisenberger MA; Luo J J Clin Oncol; 2017 Jul; 35(19):2149-2156. PubMed ID: 28384066 [TBL] [Abstract][Full Text] [Related]
9. AR-V7 in circulating tumor cells cluster as a predictive biomarker of abiraterone acetate and enzalutamide treatment in castration-resistant prostate cancer patients. Okegawa T; Ninomiya N; Masuda K; Nakamura Y; Tambo M; Nutahara K Prostate; 2018 Jun; 78(8):576-582. PubMed ID: 29508425 [TBL] [Abstract][Full Text] [Related]
10. Growth Inhibition by Testosterone in an Androgen Receptor Splice Variant-Driven Prostate Cancer Model. Nakata D; Nakayama K; Masaki T; Tanaka A; Kusaka M; Watanabe T Prostate; 2016 Dec; 76(16):1536-1545. PubMed ID: 27473672 [TBL] [Abstract][Full Text] [Related]
11. Analytic Validation of RNA In Situ Hybridization (RISH) for AR and AR-V7 Expression in Human Prostate Cancer. Guedes LB; Morais CL; Almutairi F; Haffner MC; Zheng Q; Isaacs JT; Antonarakis ES; Lu C; Tsai H; Luo J; De Marzo AM; Lotan TL Clin Cancer Res; 2016 Sep; 22(18):4651-63. PubMed ID: 27166397 [TBL] [Abstract][Full Text] [Related]
12. Androgen-receptor splice variant-7-positive prostate cancer: a novel molecular subtype with markedly worse androgen-deprivation therapy outcomes in newly diagnosed patients. Li H; Wang Z; Xiao W; Yan L; Guan W; Hu Z; Wu L; Huang Q; Wang J; Xu H; Zhang X; Ye Z Mod Pathol; 2018 Jan; 31(1):198-208. PubMed ID: 29076496 [TBL] [Abstract][Full Text] [Related]
13. Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer. Sharp A; Welti JC; Lambros MBK; Dolling D; Rodrigues DN; Pope L; Aversa C; Figueiredo I; Fraser J; Ahmad Z; Lu C; Rescigno P; Kolinsky M; Bertan C; Seed G; Riisnaes R; Miranda S; Crespo M; Pereira R; Ferreira A; Fowler G; Ebbs B; Flohr P; Neeb A; Bianchini D; Petremolo A; Sumanasuriya S; Paschalis A; Mateo J; Tunariu N; Yuan W; Carreira S; Plymate SR; Luo J; de Bono JS Eur Urol; 2019 Nov; 76(5):676-685. PubMed ID: 31036442 [TBL] [Abstract][Full Text] [Related]
14. Serial blood-based analysis of AR-V7 in men with advanced prostate cancer. Nakazawa M; Lu C; Chen Y; Paller CJ; Carducci MA; Eisenberger MA; Luo J; Antonarakis ES Ann Oncol; 2015 Sep; 26(9):1859-1865. PubMed ID: 26117829 [TBL] [Abstract][Full Text] [Related]
15. Association of AR-V7 and Prostate-Specific Antigen RNA Levels in Blood with Efficacy of Abiraterone Acetate and Enzalutamide Treatment in Men with Prostate Cancer. Qu F; Xie W; Nakabayashi M; Zhang H; Jeong SH; Wang X; Komura K; Sweeney CJ; Sartor O; Lee GM; Kantoff PW Clin Cancer Res; 2017 Feb; 23(3):726-734. PubMed ID: 27489290 [TBL] [Abstract][Full Text] [Related]
16. Prognostic Value of Androgen Receptor Splice Variant 7 in the Treatment of Castration-resistant Prostate Cancer with Next generation Androgen Receptor Signal Inhibition: A Systematic Review and Meta-analysis. Li H; Wang Z; Tang K; Zhou H; Liu H; Yan L; Guan W; Chen K; Xu H; Ye Z Eur Urol Focus; 2018 Jul; 4(4):529-539. PubMed ID: 28753843 [TBL] [Abstract][Full Text] [Related]
17. [ARV-7: A biomarker for the treatment of metastatic castration-resistant prostate cancer]. Chen ZY; Dong Q; Liu LR; Wei Q Zhonghua Nan Ke Xue; 2019 Feb; 25(2):172-176. PubMed ID: 32216207 [TBL] [Abstract][Full Text] [Related]
18. Analytical Validation and Clinical Qualification of a New Immunohistochemical Assay for Androgen Receptor Splice Variant-7 Protein Expression in Metastatic Castration-resistant Prostate Cancer. Welti J; Rodrigues DN; Sharp A; Sun S; Lorente D; Riisnaes R; Figueiredo I; Zafeiriou Z; Rescigno P; de Bono JS; Plymate SR Eur Urol; 2016 Oct; 70(4):599-608. PubMed ID: 27117751 [TBL] [Abstract][Full Text] [Related]
19. Overexpression of nuclear AR-V7 protein in primary prostate cancer is an independent negative prognostic marker in men with high-risk disease receiving adjuvant therapy. Chen X; Bernemann C; Tolkach Y; Heller M; Nientiedt C; Falkenstein M; Herpel E; Jenzer M; Grüllich C; Jäger D; Sültmann H; Duensing A; Perner S; Cronauer MV; Stephan C; Debus J; Schrader AJ; Kristiansen G; Hohenfellner M; Duensing S Urol Oncol; 2018 Apr; 36(4):161.e19-161.e30. PubMed ID: 29198908 [TBL] [Abstract][Full Text] [Related]
20. Nuclear-specific AR-V7 Protein Localization is Necessary to Guide Treatment Selection in Metastatic Castration-resistant Prostate Cancer. Scher HI; Graf RP; Schreiber NA; McLaughlin B; Lu D; Louw J; Danila DC; Dugan L; Johnson A; Heller G; Fleisher M; Dittamore R Eur Urol; 2017 Jun; 71(6):874-882. PubMed ID: 27979426 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]